EcoDrugPlus

Group 10 Secretory Phospholipase A2

Ensembl ID : ENSNGAG00000006491
Gene Symbol: LOC103731556
3 Cross references
249 Possible Orthologues:

Growth Hormone Releasing Hormone Receptor

Ensembl ID : ENSNGAG00000018741
Gene Symbol: GHRHR
3 Cross references
191 Possible Orthologues:

Growth Hormone Secretagogue Receptor

Ensembl ID : ENSNGAG00000016912
Gene Symbol: GHSR
3 Cross references
212 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSNGAG00000017859
Gene Symbol: GUCY1A1
3 Cross references
202 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSNGAG00000004842
Gene Symbol: GUCY1A2
3 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSNGAG00000019662
Gene Symbol: GUCY1B1
3 Cross references
209 Possible Orthologues:

Heat Shock Protein 90 Alpha Family Class A Member 1

Ensembl ID : ENSNGAG00000013224
Gene Symbol: HSP90AA1
3 Cross references
212 Possible Orthologues:

Heat Shock Protein 90 Alpha Family Class B Member 1

Ensembl ID : ENSNGAG00000017929
Gene Symbol: HSP90AB1
3 Cross references
198 Possible Orthologues:

High Mobility Group Box 1

Ensembl ID : ENSNGAG00000020735
Gene Symbol: HMGB1
2 Cross references
212 Possible Orthologues:

Histamine Receptor H1

Ensembl ID : ENSNGAG00000021456
Gene Symbol: HRH1
3 Cross references
186 Possible Orthologues:

Histamine Receptor H2

Ensembl ID : ENSNGAG00000018742
Gene Symbol: HRH2
3 Cross references
249 Possible Orthologues:

Histamine Receptor H3

Ensembl ID : ENSNGAG00000019357
Gene Symbol: HRH3
3 Cross references
117 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).